In metabolic fatty liver disease (MASLD), fatty liver inflammation (MASH), and hepatocellular carcinoma (HCC), transcriptomic analyses revealed significantly downregulated RASSF4 expression. This evidence concerns the gene RASSF4 and hepatocellular carcinoma.